Fosun Pharma, the promoter of Gland Pharma, is set to reduce its stake in the Indian pharmaceutical company. Reports indicate the firm plans to divest a 5% equity interest, aiming to raise nearly Rs 2,279.5 crore through a strategic block trade.
The transaction is reportedly priced at Rs 2,763 per share. This move follows a period of positive momentum for Gland Pharma, which recently unveiled a robust financial performance, posting a 47% increase in profit for the first quarter of fiscal year 2027.
Known for its global manufacturing reach and high-end research capabilities, Gland Pharma remains a significant player in the injectable drug market. Market participants are closely watching the block deal, as it marks a notable shift in the shareholding structure of the Hyderabad-based manufacturer.
Institutional investors are expected to show interest in the offering, given the company's consistent growth trajectory and strong R&D pipeline. The completion of this deal will be a key event for shareholders navigating the current pharmaceutical equity landscape.
